Document is current
Any future updates will be listed below
-
Authors
Eggers, Michelle https://orcid.org/0000-0001-5387-2118
Vannoy, Charles H https://orcid.org/0000-0003-3617-8081
Huang, Jianyong
Purushothaman, Pravinkumar
Brassard, Jacqueline https://orcid.org/0000-0002-3305-3163
Fonck, Carlos
Meng, Hui
Prom, Mariah J
Lawlor, Michael W
Cunningham, Justine
Sadhu, Chanchal
Mavilio, Fulvio https://orcid.org/0000-0003-0459-4320
-
Funding
Funding for this research was provided by:
Audentes Therapeutics
- License Information
-
More Information
Article History
Received: 14 January 2021
Revised: 4 November 2021
Accepted: 9 November 2021
First Online: 1 December 2021
Conflict of Interest
: M.E., C.H.V., J.H., P.V., C.F., C.S., and F.M. are employees of Audentes Therapeutics, an Astellas Company. M.W.L. is or was recently a member of advisory boards for Audentes Therapeutics, Ichorion Therapeutics, and Solid Biosciences and receives or has recently received research support from these companies. M.W.L. is also a consultant for Audentes Therapeutics, Encoded Therapeutics, AGADA Biosciences, Prothelia, BioMarin, Kate Therapeutics, Lacerta Therapeutics, Affinia Therapeutics, Modis Therapeutics, Rocket Therapeutics, and Dynacure.
